Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Rating of “Hold” by Analysts

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) have received an average recommendation of “Hold” from the five analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $5.5125.

A number of research analysts recently commented on the stock. Wall Street Zen upgraded shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Coherus Oncology in a research report on Wednesday, October 8th. Finally, Oppenheimer started coverage on Coherus Oncology in a report on Thursday, January 22nd. They issued an “outperform” rating and a $10.00 price objective for the company.

Coherus Oncology Price Performance

Shares of NASDAQ CHRS opened at $2.21 on Thursday. The stock has a market cap of $267.12 million, a P/E ratio of 1.66 and a beta of 0.96. The firm’s 50-day simple moving average is $1.46 and its 200 day simple moving average is $1.37. Coherus Oncology has a fifty-two week low of $0.71 and a fifty-two week high of $2.62. The company has a quick ratio of 1.23, a current ratio of 1.24 and a debt-to-equity ratio of 0.42.

Coherus Oncology (NASDAQ:CHRS) last announced its earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.01. The company had revenue of $11.57 million during the quarter, compared to the consensus estimate of $13.41 million. Equities analysts expect that Coherus Oncology will post -1.05 EPS for the current year.

Hedge Funds Weigh In On Coherus Oncology

Several large investors have recently made changes to their positions in the business. CWM LLC raised its holdings in shares of Coherus Oncology by 13.8% in the 4th quarter. CWM LLC now owns 40,334 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 4,902 shares in the last quarter. Jefferies Financial Group Inc. increased its holdings in shares of Coherus Oncology by 2.5% in the third quarter. Jefferies Financial Group Inc. now owns 325,625 shares of the biotechnology company’s stock valued at $534,000 after buying an additional 8,000 shares in the last quarter. Corient Private Wealth LLC lifted its position in shares of Coherus Oncology by 20.0% during the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 10,000 shares during the last quarter. Tejara Capital Ltd lifted its position in shares of Coherus Oncology by 1.7% during the 2nd quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock valued at $511,000 after acquiring an additional 11,552 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of Coherus Oncology by 108.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 13,832 shares in the last quarter. Institutional investors own 72.82% of the company’s stock.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.